Pfizer pill Paxlovid becomes 1st US-authorised home COVID treatment

US health regulators on Wednesday authorised the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus.

The long-awaited milestone comes as US cases, hospitalisations and deaths are all rising and health officials warn of a tsunami of new infections from the Omicron variant that could overwhelm hospitals.

The drug, Paxlovid, is a faster, cheaper way to treat early COVID-19 infections, though initial supplies will be extremely limited. All of the previously authorised drugs against the disease require an IV or an injection.

An antiviral pill from Merck also is expected to soon win authorisation. But Pfizer’s drug is all but certain to be the preferred option because of its mild side effects and superior effectiveness, including a nearly 90 per cent reduction in hospitalisations and deaths among patients most likely to get the severe disease.

US President Joe Biden said the development marks a “significant step forward” on the path out of the pandemic.
Biden said his administration will work with states to ensure equitable distribution.

“The efficacy is high, the side effects are low and it’s oral. It checks all the boxes,” said Dr Gregory Poland of the Mayo Clinic. “You’re looking at a 90 per cent decreased risk of hospitalization and death in a high-risk group that’s stunning.

The Food and Drug Administration authorised Pfizer’s drug for adults and children ages 12 and older with a positive COVID-19 test and early symptoms who face the highest risks of hospitalisation. That includes older people and those with conditions like obesity and heart disease. Children eligible for the drug must weigh at least 88 pounds (40kg).

The pills from both Pfizer and Merck are expected to be effective against Omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.

Pfizer currently has 1,80,000 treatment courses available worldwide, with roughly 60,000 to 70,000 allocated to the US. Federal health officials are expected to ration early shipments to the hardest hit parts of the country. Pfizer said the small supply is due to the manufacturing time—currently about nine months. The company says it can halve production time next year.

The US government has agreed to purchase enough Paxlovid to treat 10 million people. Pfizer says it’s on track to produce 80 million courses globally next year, under contracts with the UK, Australia and other nations.
Health experts agree that vaccination remains the best way to protect against COVID-19. But with roughly 40 million American adults still unvaccinated, effective drugs will be critical to blunting the current and future waves of infection.

The US is now reporting more than 1,40,000 new infections daily and federal officials warn that the omicron variant could send case counts soaring. Omicron has already whipped across the country to become the dominant strain, federal officials confirmed earlier this week.

Against that backdrop, experts warn that Paxlovid’s initial impact could be limited.
For more than a year, biotech-engineered antibody drugs have been the go-to treatments for COVID-19. But they are expensive, hard to produce and require an injection or infusion, typically given at a hospital or clinic. Also, laboratory testing suggests the two leading antibody drugs used in the US aren’t effective against omicron.

Pfizer’s pill comes with its own challenges.

Patients will need a positive COVID-19 test to get a prescription. And Paxlovid has only proven effective if given within five days of symptoms appearing. With testing supplies stretched, experts worry it may be unrealistic for patients to self-diagnose, get tested, see a physician and pick up a prescription within that narrow window.

“If you go outside that window of time I fully expect the effectiveness of this drug is going to fall,” said Andrew Pekosz, a Johns Hopkins University virologist.
The FDA based its decision on company results from a 2,250-patient trial that showed the pill cut hospitalisations and deaths by 89 per cent when given to people with mild-to-moderate COVID-19 within three days of symptoms. Less than 1 per cent of patients taking the drug were hospitalised and none died at the end of the 30-day study period, compared with 6.5 per cent of patients hospitalised in the group getting a dummy pill, which included nine deaths.

Pfizer’s drug is part of a decades-old family of antiviral drugs known as protease inhibitors, which revolutionised the treatment of HIV and hepatitis C. The drugs block a key enzyme which viruses need to multiply in the human body.

The US will pay about $500 for each course of Pfizer’s treatment, which consists of three pills taken twice a day for five days. Two of the pills are Paxlovid and the third is a different antiviral that helps boost levels of the main drug in the body.